People · Operator
Named in public records as an officer, director or promoter · active 2010–2020 · Other Health Care, Biotechnology, Pharmaceuticals, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gynesonics, Inc | — | Other Health Care | Series C | $299.1M | $1.0B | 2010 |
| Orca BioSystems Inc | — | Other Health Care | Series D+ | $192.0M | $4.4B | 2019 |
| Dicerna Pharmaceuticals Inc | — | Biotechnology | Series C | $118.9M | $2.5B | 2013 |
| Forty Seven, Inc. | — | Pharmaceuticals | Series C | $109.1M | $2.6B | 2015 |
| Personalis, Inc. | — | Biotechnology | Series B | $68.9M | $485.2M | 2011 |
| Palo Alto Health Sciences, Inc. | — | Healthtech | Series B | $49.6M | $166.0M | 2015 |
| D2G Oncology, Inc. | — | Biotechnology | Series A | $8.7M | $316.3M | 2020 |
Jonathan MacQuitty at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jonathan MacQuitty on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Brown | 1 | 22 |
| JEFFREY SCHWARTZ | 1 | 9 |
| Stephen Bruso | 1 | 9 |
| Joyce Erony | 1 | 8 |
| Alex Kolicich | 1 | 8 |
| Ned Scheetz | 1 | 8 |
| Stephen Hoffman | 1 | 7 |
| David Neustaedter | 1 | 7 |
| Chris Schaepe | 1 | 6 |
| Christopher Schaepe | 1 | 6 |
| JON FEIBER | 1 | 5 |
| Russell Siegelman | 1 | 5 |
| Brian K. Halak | 1 | 5 |
| Eric Jensen | 1 | 5 |
| Jeffrey Bird | 1 | 5 |
| DENNIS HENNER | 1 | 5 |
| Tom Rodgers | 1 | 4 |
| Andrew Chung | 1 | 4 |
| Dennis H. Langer | 1 | 3 |
| Ken Ludlum | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.